
Unbeknownst to Zelensky, Trump Announces Ceasefire Between Russia and Ukraine on Energy Infrastructure
By SHARON KEHNEMUI
|A normally hard-headed bench just endorsed President Biden’s scheme to dictate how much drugmakers can charge under Medicare.

What’s come over the Second Circuit? The riders of the federal court’s appeals circuit have often been a judicial bulwark against some of liberalism’s most egregious excesses in policy and law. Yet a panel of circuit judges just endorsed President Biden’s scheme to dictate how much drugmakers can charge under the Medicare program. The ruling swings behind federal price controls, traversing the laws of economics while also endangering medical innovation.

By SHARON KEHNEMUI
|
By MATTHEW RICE
|
By ROSS ANDERSON
|
By SHARON KEHNEMUI
|
By TOM DEIGNAN
|
By GEORGE WILLIS
|
By JOSEPH CURL
|
By MICHAEL BARONE
|What’s come over the Second Circuit? The riders of the federal court’s appeals circuit have often been a judicial bulwark against some of liberalism’s most egregious excesses in policy and law. Yet a panel of circuit judges just endorsed President Biden’s scheme to dictate how much drugmakers can charge under the Medicare program. The ruling swings behind federal price controls, traversing the laws of economics while also endangering medical innovation.
Already have a subscription? Sign in to continue reading
Cancel anytime
By continuing you agree to our Privacy Policy and Terms of Service.
Cancel anytime